EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib

Ping Wang, Hao Xi Lucas Tang, Jiaqin Song, Yuyan Yang, Yao Yao, Lei Xia

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2025.218100 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Letters, 2026. Verfasst von Ping Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 40…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Adenocarcinoma of Lung, Lung Neoplasms, Pyrazoles. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report a rare case of advanced lung adenocarcinoma harboring a novel non-canonical RET::FOXJ3 gene fusion, which has not been previously documented. A 66-year-old male was diagnosed with stage IVB non-small cell lung cancer (NSCLC). Next-generation sequencing (NGS) analysis using the Illumina NovaSeq 6000 identified a previously unreported rearrangement of RET (Rearranged During Transfection) proto-oncogene, involving a fusion of RET exon 1 to FOXJ3 (Forkhead box J3) exons 2-13. Following disease progression on first-line chemotherapy combined with PD-L1 blockage (PFS1 = 6 months), the patient was treated with the selective RET inhibitor pralsetinib (PFS2 = 2 months). However, no significant clinical response was observed, and disease progression was reassessed after 6 weeks of targeted therapy. Palliative cranial radiotherapy was subsequently administered for newly developed brain metastases (PFS3 = 5 months), resulting in an overall survival of 18 months (OS = 18 months). This case expands the current understanding of RET fusion partners and raises important questions regarding the functional and therapeutic implications of non-canonical fusions. It underscores the necessity of corroborating DNA-level findings with RNA and/or protein expression data and highlights the limitations of existing RET-targeted therapies for atypical RET fusions that may lack an intact kinase domain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-retAdenocarcinoma of LungLung NeoplasmsPyrazolesOncogene Proteins, FusionPyrimidinesHumansMaleAgedProto-Oncogene MasPyridines

Stichwörter der Autor:innen

Lung adenocarcinomaNext-generation sequencingNovel RET::FOXJ3 fusionPralsetinibRET inhibitorRNA-Level validation

Substanzen

Proto-Oncogene Proteins c-retRET protein, humanpralsetinibProto-Oncogene MasMAS1 protein, humanPyrazolesOncogene Proteins, FusionPyrimidinesPyridines

Autor:innen und Institutionen

  • Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 401336, China.
  • Department of Biological Sciences, Faculty of Science, National University of Singapore, 14 Science Drive 4, 117543, Singapore.
  • Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 401336, China; Department of Biological Sciences, Faculty of Science, Na…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, P., Tang, H. X. L., Song, J., Yang, Y., Yao, Y., & Xia, L. (2026). Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218100

Vancouver

Wang P, Tang HXL, Song J, Yang Y, Yao Y, Xia L. Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218100

BibTeX
@article{Wang2026,
  author = {Wang, Ping and Tang, Hao Xi Lucas and Song, Jiaqin and Yang, Yuyan and Yao, Yao and Xia, Lei},
  title = {Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2025.218100}
}
Kostenlos starten →